Rhumbline Advisers Purchases 5,402 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Rhumbline Advisers raised its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 6.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 91,933 shares of the biotechnology company's stock after purchasing an additional 5,402 shares during the period. Rhumbline Advisers owned 0.14% of Blueprint Medicines worth $8,137,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in shares of Blueprint Medicines by 11,972.8% in the first quarter. GAMMA Investing LLC now owns 28,854 shares of the biotechnology company's stock valued at $2,554,000 after purchasing an additional 28,615 shares in the last quarter. California State Teachers Retirement System lifted its stake in shares of Blueprint Medicines by 4.9% during the fourth quarter. California State Teachers Retirement System now owns 59,259 shares of the biotechnology company's stock valued at $5,169,000 after buying an additional 2,742 shares during the period. Mackenzie Financial Corp lifted its stake in shares of Blueprint Medicines by 99.6% during the fourth quarter. Mackenzie Financial Corp now owns 14,177 shares of the biotechnology company's stock valued at $1,237,000 after buying an additional 7,076 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Blueprint Medicines during the fourth quarter valued at approximately $116,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Blueprint Medicines by 5.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,946 shares of the biotechnology company's stock valued at $20,928,000 after buying an additional 12,035 shares during the period.

Insider Buying and Selling

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the sale, the chief operating officer now directly owns 69,266 shares in the company, valued at $6,581,655.32. The trade was a 3.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of Blueprint Medicines stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $101.14, for a total transaction of $505,700.00. Following the completion of the transaction, the director now directly owns 146,630 shares in the company, valued at approximately $14,830,158.20. This represents a 3.30% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 14,574 shares of company stock worth $1,465,528. 4.21% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Morgan Stanley increased their price target on shares of Blueprint Medicines from $102.00 to $129.00 and gave the stock an "equal weight" rating in a research note on Thursday, June 5th. TD Cowen lowered shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, June 3rd. Needham & Company LLC lowered shares of Blueprint Medicines from a "buy" rating to a "hold" rating and set a $130.00 price target for the company. in a report on Monday, June 2nd. Cowen lowered shares of Blueprint Medicines to a "hold" rating in a report on Monday, June 2nd. Finally, Scotiabank downgraded shares of Blueprint Medicines from a "strong-buy" rating to a "sector perform" rating and set a $135.00 price objective on the stock. in a research note on Monday, June 2nd. Seventeen analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $129.35.

Blueprint Medicines Price Performance

Shares of BPMC traded down $0.25 during mid-day trading on Friday, hitting $127.96. The company's stock had a trading volume of 4,731,774 shares, compared to its average volume of 1,202,713. The firm has a 50-day moving average price of $100.02 and a 200 day moving average price of $97.02. The stock has a market capitalization of $8.26 billion, a price-to-earnings ratio of -118.48 and a beta of 0.84. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. Blueprint Medicines Co. has a fifty-two week low of $73.04 and a fifty-two week high of $128.34.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The firm had revenue of $149.41 million during the quarter, compared to analysts' expectations of $158.31 million. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The business's revenue was up 55.5% on a year-over-year basis. During the same period last year, the business earned $1.40 earnings per share. On average, research analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.